Figure 7 | Leukemia

Figure 7

From: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

Figure 7

Synergistic effect of tofacitinib in combination with MEK or Bcl-2 inhibitors in JAK3 mutant PDX samples. (a) Schematic representation of experimental workflow. (b) Chou-Talalay plots showing the effect of tofacitinib with MEK inhibitors (selumetinib, trametinib) or Bcl-2 inhibitor (ABT-199) on T-ALL-derived PDX samples. CompuSyn was used to calculate the combination index (CI). CI<1 indicate synergistic effects, C=1 indicate additive effects, C>1 indicate antagonistic effects. (c–e) Relative viable cell count is after 48 h treatment of PDX samples with a combination of 0.2 μM tofacitinib and 0.3 μM selumetinib (c) or 0.2 μM trametinib (d) or a combination with 0.3 μM tofacitinib and 0.13 μM ABT-199 (e). Data represents the average of three experiments±s.e.m. Significance was calculated using one-way analysis of variance (ANOVA) and the Bonferroni correction. (****P⩽0.0001; ***P⩽0.001; nonsignificant (ns) P⩾0.05).

Back to article page